Acute Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity
Trial Parameters
Brief Summary
The primary objectives of this pilot study are to test if a single dose of an oral ketone monoester supplement will increase blood flow and connectivity in the brain in adults with subjective cognitive decline (SCD) or mild cognitive impairment (MCI). The main questions it aims to answer are: Does a single dose of an oral ketone supplement increase global cerebral blood flow (CBF)? Does a single dose of an oral ketone supplement improve resting-state functional connectivity in the Default Mode Network (DMN)? Does the increase in CBF positively correlate with improved functional connectivity in the DMN? Participants will: * Attend one 2-hour session, which includes: * Neurocognitive assessment * MRI Scans (two, each 15 Minutes) * Capillary blood ketone level measurements * Hemodynamic assessment (blood pressure, heart rate)
Eligibility Criteria
Inclusion Criteria: * Adults aged 55 years or older * Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI) SCD CRITERIA: * Self-experienced, persistent decline of cognitive abilities within the last 5 years in relation to a previously normal status * Normal results on demographically adjusted standardized cognitive tests * Accompanied by concerns associated with SCD and a feeling of worse performance than others in the same age group * Decline must not be related to a specific event or explained by a specific disease, medical disorder, medication, or substance abuse MCI CRITERIA * Fulfils criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5): * Demographically adjusted performance between -1 and -2 SD below average in one or more cognitive domains on standardized cognitive tests * Accompanied by concern from the individual, a knowledgeable informant, or clinician indicating mild cognitive decline * Capacity for independent daily activities is ma